8-K: Current report filing

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20509

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

March 10, 1999
Date of Report
(Date of Earliest Event Reported)

BISHOP EQUITIES, INC.
(Exact Name of Registrant as Specified in its Charter)

Nevada 33-44567-NY 13-3632859
(State or other juris- (Commission File No.) (IRS Employer
diction of incorporation) I.D.No.)

7825 Fay Avenue, Suite 200
La Jolla, California 92037
(Address of Principal Executive Offices)

(619) 456-5777
Registrant's Telephone Number


ITEM 1. CHANGES IN CONTROL OF REGISTRANT.

(a) On March 10, 1999, the Registrant executed an Agreement and Plan of
Reorganization for the Acquisition of All of the Outstanding Stock (the "Aethlon
Agreement") of Aethlon, Inc., a California corporation ("Aethlon") whereby the
Registrant acquired approximately 92% of the outstanding shares of common stock
of Aethlon in exchange for shares of Common Stock of the Registrant (the "Bishop
Shares"). Pursuant to the Aethlon Agreement, Aethlon became a majority owned
subsidiary of the Registrant.

Also on March 10, 1999, the Registrant executed an Agreement and Plan of
Reorganization for the Acquisition of All of the Outstanding Stock (the "Hemex
Agreement") of Hemex, Inc., a Delaware corporation ("Hemex") whereby the
Registrant acquired approximately 83% of the outstanding shares of common stock
of Hemex in exchange for Bishop Shares. Pursuant to the Hemex Agreement, Hemex
became a majority owned subsidiary of the Registrant.

The Registrant issued a total of 675,000 Bishop Shares to the former
shareholders of Aethlon and 1,123,211 Bishop Shares to the former shareholders
of Hemex as of March 10, 1999.

The Aethlon Agreement provides that the Registrant may issue an additional
58,500 Bishop Shares to acquire the remaining 8% of Aethlon. The Hemex Agreement
provides that the Registrant may issue an additional 243,000 Bishop Shares to
acquire the remaining 17% of Hemex. It is the intention of the Registrant's
management ("Management") to continue to attempt to acquire 100% of the
outstanding shares of Aethlon and Hemex on the same terms and conditions
afforded the Aethlon and Hemex shareholders who have already become parties to
the Hemex Agreement and the Aethlon Agreement, respectively (the Hemex Agreement
and the Aethlon Agreement are collectively referred to as the "Plan").

As of March 10, 1999, shareholders representing 1,798,211 of the 2,083,500
shares to be issued under the Plan (approximately 86% of the Registrant's
shareholders as of March 10, 1999) had executed and delivered the Plan. Taking
into account the 1,798,211 shares of "restricted securities" of the Registrant
issued under the Plan on March 10, 1999, there are currently 2,309,711 shares of
common stock of the Registrant issued and outstanding. Assuming that all of the
shareholders of Aethlon and Hemex enter into the Plan, there will be a total of
2,595,000 shares of Registrant outstanding.

The Plan was approved by the Board of Directors of the Company on
February 22, 1999.

The former principal shareholders of the Registrant and their percentage
of ownership of the outstanding voting securities of the Registrant prior to
the completion of the Plan were: Deborah A. Salerno, former President and
Director, owned 425,000 shares of the Registrant (83%), and Maureen Abato,
former Secretary/Treasurer and Director owned 75,000 shares of the Registrant
(15%).

The source of the consideration used by the Aethlon and Hemex shareholders
to acquire their respective interests in the Registrant was the
exchange of their outstanding shares of common stock of Aethlon and Hemex
pursuant to the Plan.

The basis of the "control" by the Aethlon and Hemex shareholders is
Stock ownership or positions held. Pursuant to the Plan, the then members of
The Board of Directors and executive officers resigned, in seriatim, and the
persons named in paragraph (b) below were designated to serve as directors and
executive officers of the Registrant, until the next respective annual
meetings of the shareholders and directors of the Registrant or until their
prior resignations or terminations.

The new members of the Board of Directors have adopted a resolution to
amend the Registrants Articles of Incorporation to change the name of the
Registrant to "Aethlon Medical, Inc." subject to shareholder approval.

(b) To the knowledge of Management and based upon a review of the
stock ledger maintained by the Registrant's transfer agent and registrar, the
following table sets forth the beneficial ownership of persons who own more
than five percent of the Registrant's common stock as of the date hereof, and
the share holdings of new Management:

Percent
Number of
Name Title of Shares(1) Class

James A. Joyce Chairman, Secretary, 675,400 29.2%
and Director

Franklyn S. Barry, Jr. President/Chief Executive 418,593 (2) 15.4% (2)
Officer, Interim Chief Financial
Officer, and Director

Edward G. Broenniman Director 255,874 (3) 11.1%

Clara Ambrus Chief Scientific Officer and 450,279 19.5%
Director of Hemex

Thomas Wolf Shareholder 131,820 5.7%

All directors and executive 1,349,867 (4) 49.6% (4)
officers of Registrant as a group
(3 persons)

(1) Assumes 2,309,711 shares outstanding.
(2) Includes 412,500 shares issuable upon the exercise of presently-exercisable
incentive stock options. The percentage ownership is based on 2,722,211
shares outstanding, assuming the exercise of the 412,500 options.
(3) Includes 201,989 shares owned of record by Linda Broenniman, Mr.
Broenniman's wife.
(4) Includes 412,500 shares issuable upon the exercise of presently-exercisable
incentive stock options held by Mr. Barry. The percentage ownership is
based on 2,722,211 shares outstanding, assuming the exercise of the 412,500
options.

ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.

See Item 1 of this Report. The consideration exchanged under the
Plan was negotiated at "arms length" between the directors and executive
officers of the Registrant and Aethlon and Hemex, respectively. The members of
the Board of Directors of the Registrant used criteria utilized in similar
proposals involving the Registrant in the past, including the relative value of
the assets of the Registrant; its present and past business operations; the
future potential of Aethlon and Hemex; its management; and the potential
benefit to the shareholders of the Registrant. The members of the Board of
Directors determined in good faith that the consideration for the exchange was
reasonable, under these circumstances.

No director, executive officer or person who may be deemed to be an
affiliate of the Registrant had any direct or indirect interest in either
Aethlon or Hemex prior to the completion of the Plan.

Business

Aethlon, incorporated in July 1998 under the laws of the State of
California, was formed for the purpose of acquiring proprietary medical device
technologies that it believes can be successfully developed and commercialized
on an international basis. Prior to entering into the Plan, Aethlon had entered
into an agreement with Hemex to provide interim funding and to acquire Hemex in
accordance with the Plan.

Hemex was incorporated in 1995 under the laws of the State of Delaware to
develop and commercialize proprietary medical devices capable of removing
harmful metal intoxicants and other contaminants from human blood. The
commercialization of the Hemex HemopurifierTM, which removes targeted metal
intoxicants in an extracorporeal (outside the body) fashion, will be the initial
focus of the Registrant.